reference/23410887

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/23410887

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	2311
issn	0300-7995 1473-4877
issueIdentifier	11
pageRange	2301-2311
publicationName	Current Medical Research and Opinion
startingPage	2301
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c81c82b4ad9caa060230b3c9689699b7 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_916de93fe8f49855f42e16db43537393
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_113c2d9af91b6dcc9c173bde5e612e46 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f99b70285d5766868a7e362e9d4e11f1 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_54b82c7f1b5351db98e0d71dd5462c2a http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_a2c69a466332c767b1f1e2301b3ff0d5
bibliographicCitation	Crivera C, Suh DC, Huang ES, Cagliero E, Grant RW, Vo L, Shin HC, Meigs JB. The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients. Current Medical Research and Opinion. 2006 Oct 16;22(11):2301–11. doi: 10.1185/030079906x132523.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_59330d13c5c3c756a2330e2fb9d1af30 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_235c7253c0fc8fbeddd4c3c145843171 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9da6ac6425d6d7bb7c3b7e601a9ac7e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_283a28c9064273eb32f19b9907c4e19f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_469e61846644370787746245103958bb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_456e425401d0ecf8a90ce6cff9b26080 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_646fa630f174ccc997ee0ee576297c31 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bd8729b011b73e7633c57b53d618a29c
date	2006-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1185/030079906x132523 https://pubmed.ncbi.nlm.nih.gov/PMC2291353 https://pubmed.ncbi.nlm.nih.gov/17076990
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3218 https://portal.issn.org/resource/ISSN/1473-4877 https://portal.issn.org/resource/ISSN/0300-7995
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D003924Q000188 http://id.nlm.nih.gov/mesh/D016527
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006949Q000188 http://id.nlm.nih.gov/mesh/D011787 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000465 http://id.nlm.nih.gov/mesh/D019233 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D012189 http://id.nlm.nih.gov/mesh/D017048 http://id.nlm.nih.gov/mesh/D003924Q000175 http://id.nlm.nih.gov/mesh/D019411Q000191 http://id.nlm.nih.gov/mesh/D017410 http://id.nlm.nih.gov/mesh/D006040 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006973Q000188 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D006943Q000188
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5793 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8078 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8102 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5997 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7440 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7444 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7181 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8072

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127563695 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128121087 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129621433

Total number of triples: 65.